PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors
Background The prototypical type I natural killer T (NKT) cell agonist, α-galactosylceramide (α-GalCer), has shown only minimal effects against solid tumors in the clinic. The most promising clinical application of α-GalCer currently entails ex vivo priming of patient-derived dendritic cells; howeve...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2025-03-01
|
| Colecção: | Journal for ImmunoTherapy of Cancer |
| Acesso em linha: | https://jitc.bmj.com/content/13/3/e009539.full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|